• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Neuraxis Inc.

    10/8/24 7:30:11 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NRXS alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    Neuraxis, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

     

    (Title of Class of Securities)

     

    64134X201

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (continued on the following pages)

     

     

     

     
     

     

    CUSIP No. 64134X201 13G  

     

    1

    NAMES OF REPORTING PERSONS

     

    Brian P. Hannasch

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ☐    

     

    (b) ☐    

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    695,753 (1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    695,753 (1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    695,753 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐

     

    N/A

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    10.2% (1)(2)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

     

     

    (1) Includes 12,852 shares of common stock of Neuraxis, Inc. (the “Issuer”) issuable upon the exercise of currently exercisable warrants held by Mr. Hannasch (the “Warrant Shares”).
       
    (2) Based on 6,841,621 outstanding shares of the Issuer’s common stock as of August 8, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the period ended June 30, 2024, filed with the Securities and Exchange Commission on August 9, 2024, plus the Warrant Shares.

     

     
     

     

    Item 1.

     

      (a) Name of Issuer

     

    Neuraxis, Inc. (the “Issuer”)

     

      (b) Address of Issuer’s Principal Executive Offices

     

    11611 N. Meridian Street, Suite 330

    Carmel, Indiana 46032

     

    Item 2.

     

      (a) Name of Person Filing

     

    Brian P. Hannasch

     

      (b) Address of Principal Business Office or, if none, Residence

     

    8815 W. State Road 46

    Columbus, Indiana 47201

     

      (c) Citizenship

     

    United States

     

      (d) Title of Class of Securities

     

    Common Stock, par value $0.001 per share (“Common Stock”)

     

      (e) CUSIP Number

     

    64134X201

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act;
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act;
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act;
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
           
      (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act;
           
      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

     
     

     

    Item 4. Ownership

     

      (a) Amount Beneficially Owned

     

    695,753 shares (1)

     

      (b) Percent of Class

     

    10.2% (1)(2)

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote

     

    695,753 shares (1)

     

      (ii) Shared power to vote or to direct the vote

     

    0 shares

     

      (iii) Sole power to dispose or to direct the disposition of

     

    695,753 shares (1)

     

      (iv) Shared power to dispose or to direct the disposition of

     

    0 shares

     

     

    (1) Includes 12,852 shares of Common Stock issuable upon the exercise of currently exercisable warrants held by Mr. Hannasch (the “Warrant Shares”).
       
    (2) Based on 6,841,621 outstanding shares of the Common Stock as of August 8, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the period ended June 30, 2024, filed with the Securities and Exchange Commission on August 9, 2024, plus the Warrant Shares.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Not Applicable

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:

    October 8, 2024

     
         
    By: /s/ Brian P. Hannasch  
      Brian P. Hannasch  

     

     

    Get the next $NRXS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRXS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CMO, SVP Science & Tech Miranda Adrian

    4 - Neuraxis, INC (0001933567) (Issuer)

    3/2/26 4:10:28 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Watkins Bradley Mitchell was granted 21,598 shares, increasing direct ownership by 87% to 46,335 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    2/26/26 9:23:33 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by CRO, CCO, CPO Carrico Thomas Joeseph

    4 - Neuraxis, INC (0001933567) (Issuer)

    2/26/26 9:23:14 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025. 4Q25 Financial Highlights Revenues increased 27% year over year to $968 thousand in 4Q25.Operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and compensation expenses to facilitate growth.  Cash balance was $5.0 million as of December 31, 2025. FY2025 Financial Highlights

    3/19/26 7:05:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026

    CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2025, for the period ended December 31, 2025, on Thursday, March 19, 2026, before market open. The Company has scheduled a conference call for the same day, Thursday, March 19, 2026, at 9:00 am ET to review the results. Conference Call Details Date and Time: Thursday, March 19, 2026, at 9:00am ET Live Webcast Information: Interested parties can access the confere

    3/12/26 9:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway

    The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.The assignment of a Category I CPT® code demonstrates a strong message to payers, both commercial and government, that there is now a path to consistent reporting and reimbursement for providers in the medical community. CARMEL, Ind., Jan. 08, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) is now

    1/8/26 8:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hannasch Brian bought $382,800 worth of shares (80,000 units at $4.79), increasing direct ownership by 7% to 1,211,522 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    2/13/26 4:04:28 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Aharon Gil bought $1,007,206 worth of shares (286,138 units at $3.52) (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    12/29/25 5:12:04 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Hannasch Brian bought $800,001 worth of shares (355,556 units at $2.25), increasing direct ownership by 46% to 1,131,522 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    7/3/25 11:24:27 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    SEC Filings

    View All

    SEC Form 10-K filed by Neuraxis Inc.

    10-K - Neuraxis, INC (0001933567) (Filer)

    3/19/26 7:00:34 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.

    SCHEDULE 13G/A - Neuraxis, INC (0001933567) (Subject)

    2/3/26 6:45:24 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.

    SCHEDULE 13G/A - Neuraxis, INC (0001933567) (Subject)

    11/12/25 8:27:21 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Leadership Updates

    Live Leadership Updates

    View All

    NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

    CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024. As part of his appointment, Mr. Henrichs has resigned as an independent director on the board of NeurAxis (the "Board"). "We are thrilled to announce Tim as the new Chief Financial Officer of NeurAxis," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "His extensive experience will be highly valuable

    1/31/24 9:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Financials

    Live finance-specific insights

    View All

    NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025. 4Q25 Financial Highlights Revenues increased 27% year over year to $968 thousand in 4Q25.Operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and compensation expenses to facilitate growth.  Cash balance was $5.0 million as of December 31, 2025. FY2025 Financial Highlights

    3/19/26 7:05:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026

    CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2025, for the period ended December 31, 2025, on Thursday, March 19, 2026, before market open. The Company has scheduled a conference call for the same day, Thursday, March 19, 2026, at 9:00 am ET to review the results. Conference Call Details Date and Time: Thursday, March 19, 2026, at 9:00am ET Live Webcast Information: Interested parties can access the confere

    3/12/26 9:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025

    CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its third quarter 2025, for the period ended September 30, 2025, on Tuesday, November 11, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, November 11, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, November 11, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live we

    11/4/25 8:30:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuraxis Inc.

    SC 13D - Neuraxis, INC (0001933567) (Subject)

    12/2/24 11:53:07 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Neuraxis Inc.

    SC 13G - Neuraxis, INC (0001933567) (Subject)

    12/2/24 9:57:28 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuraxis Inc.

    SC 13G/A - Neuraxis, INC (0001933567) (Subject)

    10/8/24 7:30:11 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care